Evidence map›Paper›PMID 35672757›Full record

ArticleCritical care (London, England)2022

An interventional quasi-experimental study to evaluate the impact of a rapid screening strategy in improving control of nosocomial extended-spectrum beta-lactamase-producing Enterobacterales and carbapenemase-producing organisms in critically ill patients.

Romain Martischang, Patrice François, Abdessalam Cherkaoui, Gesuele Renzi, Carolina Fankhauser, Jacques Schrenzel, Jérôme Pugin, Stephan Harbarth

Open access · goldAbstract read
In one paragraph

Article in Critical care (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Romain MartischangInfection Control Program, Geneva University Hospitals, Geneva, Switzerland. romainmartischang@gmail.com.
Patrice FrançoisGenomic Research Laboratory, Geneva University Hospitals, Geneva, Switzerland.
Abdessalam CherkaouiBacteriology Laboratory, Geneva University Hospitals, Geneva, Switzerland.
Gesuele RenziBacteriology Laboratory, Geneva University Hospitals, Geneva, Switzerland.
Carolina FankhauserInfection Control Program, Geneva University Hospitals, Geneva, Switzerland.
Jacques SchrenzelBacteriology Laboratory, Geneva University Hospitals, Geneva, Switzerland.
Jérôme PuginIntensive Care Units, Geneva University Hospitals, Geneva, Switzerland.
Stephan HarbarthInfection Control Program, Geneva University Hospitals, Geneva, Switzerland.
University Hospital of Geneva · CH

Funding

Swiss National Science Foundation 407240_177454
6 · The paper itself

Abstract

introductionRapid molecular tests could accelerate the control of extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-PE) and carbapenemase-producing organisms (CPO) in intensive care units (ICUs). OBJECTIVE AND

methodsThis interventional 12-month cohort study compared a loop-mediated isothermal amplification (LAMP) assay performed directly on rectal swabs with culturing methods (control period, 6 months), during routine ICU screening. Contact precautions (CP) were implemented for CPO or non-E. coli ESBL-producing Enterobacterales (nEcESBL-PE) carriers. Using survival analysis, we compared the time intervals from admission to discontinuation of unnecessary preemptive CP among patients at-risk and the time intervals from screening to implementation of CP among newly identified carriers. We also compared diagnostic performances, and nEcESBL-PE/CPO acquisition rates. This study is registered, ISRCTN 23588440.

resultsWe included 1043 patients. During the intervention and control phases, 92/147 (62.6%) and 47/86 (54.7%) of patients at-risk screened at admission were candidates for early discontinuation of preemptive CP. The LAMP assay had a positive predictive value (PPV) of 44.0% and a negative predictive value (NPV) of 99.9% for CPO, and 55.6% PPV and 98.2% NPV for nEcESBL-PE. Due to result notification and interpretation challenges, the median time from admission to discontinuation of preemptive CP increased during the interventional period from 80.5 (95% CI 71.5-132.1) to 88.3 (95% CI 57.7-103.7) hours (p = 0.47). Due to the poor PPV, we had to stop using the LAMP assay to implement CP. No difference was observed regarding the incidence of nEcESBL-PE and CPO acquisition.

conclusionA rapid screening strategy with LAMP assays performed directly on rectal swabs had no benefit for infection control in a low-endemicity setting.

Indexed as

Cross InfectionEnterobacteriaceae InfectionsBacterial Proteinsbeta-LactamasesCohort StudiesCritical IllnessHumansBacterial Proteinsbeta-LactamasescarbapenemaseClinical studyContact precautionsICUInfection controlMolecular testMultiresistant Gram-negative bacteriaScreeningSurveillance

Identifiers

PMID35672757
PMCPMC9172611
OpenAlexW4281699365

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.